Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

781. Brachytherapy for the treatment of prostate cancer: assessment report May 2005

Brachytherapy for the treatment of prostate cancer: assessment report May 2005 Brachytherapy for the treatment of prostate cancer: assessment report May 2005 Brachytherapy for the treatment of prostate cancer: assessment report May 2005 Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services (...) Advisory Committee. Brachytherapy for the treatment of prostate cancer: assessment report May 2005. Canberra: Medical Services Advisory Committee (MSAC). MSAC application no. 1089. 2006 Authors' objectives The aim of this report was to assess the safety, effectiveness and cost-effectiveness of brachytherapy for treating early localised prostate cancer compared with radical prostatectomy (RP), external beam radiation therapy (EBRT), and no initial treatment or deferred treatment (active surveillance

2006 Health Technology Assessment (HTA) Database.

782. Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing

Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation NHSC. Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives To summarise the currently available evidence on satraplatin for second-line hormone-refractory prostate cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Organoplatinum Compounds; Prostatic

2006 Health Technology Assessment (HTA) Database.

783. Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer

Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Augustovski F, Colantonio L, Pichon Riviere A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Augustovski F, Colantonio L, Pichon Riviere A. Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No.30. 2006 Authors' objectives The aim of this report was to assess current recommendations on androgen deprivation treatment for the management of prostate cancer. Authors' conclusions There is great consensus on recommending hormonal therapy

2006 Health Technology Assessment (HTA) Database.

784. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more. 1.2 It is recommended that treatment with docetaxel should be stopped: - at the completion of planned treatment of up to 10 cycles, or - if severe adverse events occur, or - in the presence of progression of disease as evidenced by clinical or laboratory criteria, or by imaging studies. 1.3 Repeat cycles of treatment with docetaxel are not recommended if the disease recurs after completion (...) Docetaxel for the treatment of hormone-refractory metastatic prostate cancer Docetaxel for the treatment of hormone-refractory metastatic prostate cancer Docetaxel for the treatment of hormone-refractory metastatic prostate cancer National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health

2006 Health Technology Assessment (HTA) Database.

785. Performance of tPSA and f/tPSA for prostate cancer in Chinese: a systematic review and meta-analysis

Performance of tPSA and f/tPSA for prostate cancer in Chinese: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

786. The cost of prostate cancer chemoprevention: a decision analysis model

of prostate cancer (PC) in men aged 55 years and older, but it was not cost-effective except in scenarios with substantial reductions in the cost of the agent and in high-risk men. In effect, given the low prevalence of disease, a substantial proportion of the cost would be generated by giving finasteride to men who, even without chemoprevention, would never develop PC. CRD COMMENTARY - Selection of comparators The rationale for the choice of the comparators was clear since the actual pattern of care (...) The cost of prostate cancer chemoprevention: a decision analysis model The cost of prostate cancer chemoprevention: a decision analysis model The cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed

2006 NHS Economic Evaluation Database.

787. Program for the treatment of prostate cancer

outcomes in men with locally advanced prostate cancer. Hormonal therapy aims to reduce the size of the tumour, making subsequent radiotherapy more effective. Laverdiere et al (1997) found that either three or six months of androgen deprivation prior to radiotherapy improved local disease control two years after treatment relative to radiotherapy alone. Another study by Pilepich et al (2001) found that four months of androgen deprivation before and during radiotherapy improved outcomes on all measures (...) included local failure and prostate-cancer-specific survival. Local failure was defined as the time to tumour recurrence, or in cases where the primary tumour never disappeared, was defined as occurring at random. In measuring prostate-cancer- specific survival, death was attributed to prostate cancer if the patient had progressive prostate cancer, otherwise the observation was censored. Secondary outcomes included distant failure, biochemical failure, disease-free survival and freedom from salvage

2006 Australia and New Zealand Horizon Scanning Network

788. Dose verification system for the measurement of radiation dose in patients undergoing radiotherapy for breast and prostate cancer

HealthPACT through funding. This Horizon scanning prioritising summary was prepared by Tom Sullivan and Tracy Merlin from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Discipline of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005. PRIORITISING SUMMARY REGISTER ID: 000227 NAME OF TECHNOLOGY: DOSE VERIFICATION SYSTEM PURPOSE AND TARGET GROUP: MEASURING THE RADIATION DOSAGE RECEIVED AT THE TUMOUR SITE IN PATIENTS WITH BREAST OR PROSTATE CANCER STAGE (...) for improving the precision of radiotherapy in the treatment of breast or prostate cancer. BACKGROUND Radiotherapy has become a conventional treatment option for patients with early and late stage cancer. The effectiveness of proton beam radiotherapy has been associated with a number of patient-level factors; including age, comorbidities, and tumour features such as location, size and aggressiveness (Siegelmann-Danieli et al 2006). Successful radiotherapy also depends on accurate radiation delivery

2006 Australia and New Zealand Horizon Scanning Network

789. Autoantibody signatures in prostate cancer. Full Text available with Trip Pro

Autoantibody signatures in prostate cancer. New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer.With a phage-display library derived from prostate-cancer tissue, we developed and used phage protein microarrays to analyze serum samples from 119 patients with prostate cancer and 138 controls, with the samples equally divided into training and validation sets. A phage-peptide detector that was constructed from the training set was evaluated (...) on an independent validation set of 128 serum samples (60 from patients with prostate cancer and 68 from controls).A 22-phage-peptide detector had 88.2 percent specificity (95 percent confidence interval, 0.78 to 0.95) and 81.6 percent sensitivity (95 percent confidence interval, 0.70 to 0.90) in discriminating between the group with prostate cancer and the control group. This panel of peptides performed better than did prostate-specific antigen (PSA) in distinguishing between the group with prostate cancer

2005 NEJM

790. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Full Text available with Trip Pro

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. The natural history of biochemical recurrence after radical prostatectomy can be long but variable. Better risk assessment models are needed to identify men who are at high risk for prostate cancer death early and who may benefit from aggressive salvage treatment and to identify men who are at low risk for prostate cancer death and can be safely observed.To define risk factors for prostate (...) cancer death following radical prostatectomy and to develop tables to risk stratify for prostate cancer-specific survival.Retrospective cohort study of 379 men who had undergone radical prostatectomy at an urban tertiary care hospital between 1982 and 2000 and who had a biochemical recurrence and after biochemical failure had at least 2 prostate-specific antigen (PSA) values at least 3 months apart in order to calculate PSA doubling time (PSADT). The mean (SD) follow-up after surgery was 10.3 (4.7

2005 JAMA

791. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Full Text available with Trip Pro

-specific mortality for the 125 men with low-risk prostate cancer (clinical tumor category T1c or T2a and PSA level <10.0 ng/mL and Gleason score < or =6) and the 233 men with higher-risk disease, stratified by the PSA velocity.A PSA velocity greater than 2.0 ng/mL per year was significantly associated with a shorter time to prostate cancer-specific mortality (adjusted hazard ratio [HR], 12.0; 95% confidence interval [CI], 3.0-54.0; P = .001) and all-cause mortality (adjusted HR, 2.1; 95% CI, 1.3-3.6; P (...) = .005) when compared with men whose PSA velocity was 2.0 ng/mL per year or less. Men presenting with low-risk disease and a PSA velocity greater than 2.0 ng/mL per year had a 7-year estimate of prostate cancer-specific mortality of 19% (95% CI, 2%-39%) compared with 0% for men whose PSA velocity was 2.0 ng/mL per year or less. The corresponding values for men with higher-risk disease were 24% (95% CI, 12%-37%) and 4% (95% CI, 0%-11%), respectively.A greater than 2.0-ng/mL increase in PSA level

2005 JAMA

792. Androgen deprivation therapy for prostate cancer. Full Text available with Trip Pro

Androgen deprivation therapy for prostate cancer. Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease.To review systematically the evidence on the risks and benefits of ADT for prostate cancer as well as clinical management (...) of its adverse effects.We performed MEDLINE searches of English-language literature (1966 to March 2005) using the terms androgen deprivation therapy, hormone treatment, and prostate cancer. We reviewed bibliographies of literature to extract other relevant articles. Studies were selected based on clinical pertinence, with an emphasis on controlled study design.Androgen deprivation therapy is effective for palliation in many patients with advanced prostate cancer and improves outcomes for high-risk

2005 JAMA

793. 20-year outcomes following conservative management of clinically localized prostate cancer. Full Text available with Trip Pro

therapy alone, stratified by age at diagnosis and histological findings.A retrospective population-based cohort study using Connecticut Tumor Registry data supplemented by hospital record and histology review of 767 men aged 55 to 74 years with clinically localized prostate cancer diagnosed between January 1, 1971, and December 31, 1984. Patients were treated with either observation or immediate or delayed androgen withdrawal therapy, with a median observation of 24 years.Probability of mortality from (...) prostate cancer or other competing medical conditions, given a patient's age at diagnosis and tumor grade.The prostate cancer mortality rate was 33 per 1000 person-years during the first 15 years of follow-up (95% confidence interval [CI], 28-38) and 18 per 1000 person-years after 15 years of follow-up (95% CI, 10-29). The mortality rates for these 2 follow-up periods were not statistically different, after adjusting for differences in tumor histology (rate ratio, 1.1; 95% CI, 0.6-1.9). Men with low

2005 JAMA

794. Educational interventions improved some quality of life outcomes in prostate cancer Full Text available with Trip Pro

of the lecture series plus 45 minutes of group discussion facilitated by a clinical psychologist and encouragement to attend lectures with a friend or family member, or usual care (UC) (n = 80). Outcomes: disease specific symptoms (sexual, urinary, and bowel functioning) (UCLA Prostate Cancer Index); patient-rated perceived bother of these outcomes; general health related QOL (physical [PCS] and mental health component scores [MCS] of the SF-36); and depressive symptoms (Center for Epidemiological Studies (...) Educational interventions improved some quality of life outcomes in prostate cancer Educational interventions improved some quality of life outcomes in prostate cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional

2005 Evidence-Based Medicine

795. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Full Text available with Trip Pro

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Vinorelbine (VRL) has been shown to be active in hormone-refractory prostate cancer (HRPC) in phase II studies, alone or in combination. Its moderate toxicity profile is well tolerated in elderly patients.Patients with metastatic prostate cancer, progressive after primary hormonal therapy, were randomised to receive intravenous VRL 30 mg/m2 on days 1 (...) -morbidities, and therefore offers an active and safe therapeutic option for patients with hormone-refractory prostate cancer.

2005 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

796. Risk of fracture after androgen deprivation for prostate cancer. Full Text available with Trip Pro

of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture.Androgen-deprivation therapy for prostate cancer (...) Risk of fracture after androgen deprivation for prostate cancer. The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied.We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received

2005 NEJM

797. Cryotherapy as a primary treatment for prostate cancer (IPG145)

.- are used as secondary codes to classify interventions that are percutaneous and require some form of image control: if the method of image control is unspecified, Y53.9 Unspecified approach to organ under image control is assigned. In addition the ICD-10 code C61.X Malignant neoplasm of prostate is assigned. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals (...) Cryotherapy as a primary treatment for prostate cancer (IPG145) Overview | Cryotherapy as a primary treatment for prostate cancer | Guidance | NICE Cryotherapy as a primary treatment for prostate cancer Interventional procedures guidance [IPG145] Published date: November 2005 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on cryotherapy as a primary treatment for prostate

2005 National Institute for Health and Clinical Excellence - Interventional Procedures

798. Low dose rate brachytherapy for localised prostate cancer (IPG132)

remains current, and should be read in conjunction with the clinical guideline. Description Prostate cancer is one of the most common cancers in men. It tends to affect older men, with the risk rising with age. It is not a single disease entity but may be indicated form an incidental biopsy finding to presentation with metastatic prostate cancer, which may or may not cause any symptoms or shorten life. Symptoms when they occur include urinary outflow obstruction and features of metastases (...) , such as bone pain. Prognosis with prostate cancer is variable and depends on the grade of the tumour and stage of the diagnosed cancer. Treatment options depend on the stage of the cancer. Current treatments for localised prostate cancer include watchful waiting, radiotherapy, and radical prostatectomy. Metastatic prostate cancer is usually treated with hormone therapy. Brachytherapy is a form of radiotherapy in which delivery of radiation is targeted directly to the prostate gland through the implantation

2005 National Institute for Health and Clinical Excellence - Interventional Procedures

799. Cryotherapy for recurrent prostate cancer (IPG119)

guidance on cryotherapy for recurrent prostate cancer remains current, and should be read in conjunction with the clinical guideline. Description This procedure is used to treat carcinoma of the prostate that has been unsuccessfully treated via another method, most typically radiation or hormones. The procedure is performed by inserting cryotherapeutic probes into the prostate gland. These are used to freeze the gland along with cancerous tissue, thus destroying the diseased tissue. Patients (...) Cryotherapy for recurrent prostate cancer (IPG119) Overview | Cryotherapy for recurrent prostate cancer | Guidance | NICE Cryotherapy for recurrent prostate cancer Interventional procedures guidance [IPG119] Published date: May 2005 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on cryotherapy for recurrent prostate cancer in May 2005. Further recommendations have been made

2005 National Institute for Health and Clinical Excellence - Interventional Procedures

800. High-intensity focused ultrasound for prostate cancer (IPG118)

High-intensity focused ultrasound for prostate cancer (IPG118) Overview | High-intensity focused ultrasound for prostate cancer | Guidance | NICE High-intensity focused ultrasound for prostate cancer Interventional procedures guidance [IPG118] Published date: March 2005 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on high-intensity focused ultrasound for prostate cancer (...) in March 2005. Further recommendations have been made as part of the clinical guideline on prostate cancer published in February 2008, as follows: High intensity focused ultrasound (HIFU) and cryotherapy are not recommended for men with localised prostate cancer other than in the context of controlled clinical trials comparing their use with established interventions. Clinical and cost-effectiveness evidence was reviewed in the development of this guideline which has led to this more specific

2005 National Institute for Health and Clinical Excellence - Interventional Procedures